Skip to main
LCTX

LCTX Stock Forecast & Price Target

LCTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lineage Cell Therapeutics is poised for success due to its strong financial results, driven by significant revenue growth and effective cost management strategies. Additionally, the company's diverse and promising pipeline, particularly with OpRegen, positions it well for continued growth and expansion in various therapeutic areas. Despite some potential risks and challenges, the company's solid partnerships, experienced management team, and advanced technologies make it a promising investment for the future.

Bears say

Lineage Cell Therapeutics is a clinical-stage biotechnology company with a proprietary, in-house cell-based manufacturing platform and promising therapies in its pipeline targeting degenerative diseases such as geographic atrophy, spinal cord injury, and sensorineural hearing loss. However, the company faces significant risks including regulatory and financial challenges, competition in the market, potential legal and intellectual property disputes, and uncertainties in gaining market share. This, combined with the lack of demonstrated visual benefit in current therapies for geographic atrophy, is why the author holds a negative outlook on the company's stock.

LCTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lineage Cell Therapeutics Inc (LCTX) Forecast

Analysts have given LCTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, LCTX has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lineage Cell Therapeutics Inc (LCTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.